US 10226512
Method for treating heart failure with preserved ejection fraction by administering human relaxin-2
granted A61KA61K38/2221A61K9/0019
Quick answer
US patent 10226512 (Method for treating heart failure with preserved ejection fraction by administering human relaxin-2) held by Relaxera Pharmazeutische Gesellschaft mbH & Co. KG expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Relaxera Pharmazeutische Gesellschaft mbH & Co. KG
- Grant date
- Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K38/2221, A61K9/0019, A61K9/006, A61K9/113